181 related articles for article (PubMed ID: 34563992)
1. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
Aramaki O; Takayama T; Moriguchi M; Sakamoto H; Yodono H; Kokudo N; Yamanaka N; Kawasaki S; Sasaki Y; Kubota K; Otsuji E; Tanaka S; Matsuyama Y; Fujii M;
Eur J Cancer; 2021 Nov; 157():373-382. PubMed ID: 34563992
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
[TBL] [Abstract][Full Text] [Related]
5. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
Gross A; Albrecht T
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
Yodono H; Matsuo K; Shinohara A
Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
[TBL] [Abstract][Full Text] [Related]
9. Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolisation of hepatocellular carcinoma.
Iwazawa J; Hashimoto N; Ohue S; Mitani T
Anticancer Res; 2012 Nov; 32(11):5039-44. PubMed ID: 23155276
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.
Molinari M; Kachura JR; Dixon E; Rajan DK; Hayeems EB; Asch MR; Benjamin MS; Sherman M; Gallinger S; Burnett B; Feld R; Chen E; Greig PD; Grant DR; Knox JJ
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
[TBL] [Abstract][Full Text] [Related]
12. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization.
Morimoto M; Kobayashi S; Moriya S; Ueno M; Tezuka S; Irie K; Goda Y; Ohkawa S
Abdom Radiol (NY); 2017 Feb; 42(2):612-619. PubMed ID: 27624498
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
Mishra G; Dev A; Paul E; Cheung W; Koukounaras J; Jhamb A; Marginson B; Lim BG; Simkin P; Borsaru A; Burnes J; Goodwin M; Ramachandra V; Spanger M; Lubel J; Gow P; Sood S; Thompson A; Ryan M; Nicoll A; Bell S; Majeed A; Kemp W; Roberts SK;
BMC Cancer; 2020 May; 20(1):483. PubMed ID: 32471447
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
17. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Kudo M; Cheng AL; Park JW; Park JH; Liang PC; Hidaka H; Izumi N; Heo J; Lee YJ; Sheen IS; Chiu CF; Arioka H; Morita S; Arai Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):37-46. PubMed ID: 28988687
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
